Of the 590 bleeding episodes included in the effectiveness assessment, 214 (36.3%) were treated with PT ± AF, 171 (29.0%) with AF only, 84 (14.2%) with rFVIIa alone, 76 (12.9%) with rFVIIa + AF, and 45 (7.6%) with rFVIIa + PT ± AF. This evidence concerns the gene F2 and atrial fibrillation.